Atossa Therapeutics, Inc. (ATOS)
Nasdaq: ATOS · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 2010
Who runs Atossa Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Quay Steven C
President & CEO. First filing Nov 2012, latest Mar 31, 2026, 4 filings in all.
Officers reporting now
3
of 8 people with a filing in the last fifteen months
Directors reporting now
5
11 people on the record since 2012
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Chen Shu-Chih | Chief Scientific Officer | Nov 2012 | May 14, 2026 | none |
| Quay Steven C | President & CEO | Nov 2012 | Mar 31, 2026 | none |
| Daniel Mark James | Chief Financial Officer | Oct 2025 | Mar 30, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Cigler Tessa | director | Mar 2024 | May 14, 2026 | none |
| Finn Jonathan | director | Nov 2023 | May 14, 2026 | none |
| Galli Stephen J | director | Nov 2012 | May 14, 2026 | none |
| Remmel H. Lawrence | director | Nov 2012 | May 14, 2026 | none |
| Steinhart Richard I | director | Mar 2014 | May 14, 2026 | none |
Earlier names on the record3, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.